Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC011248 | Panoply™ Human PAG1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC011248 | Panoply™ Human PAG1 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| LV20885L | human PAG1 (NM_018440) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH370052 | shRNA set against Mouse PAG1 (NM_053182.5) | Inquiry |
| SHH370048 | shRNA set against Human PAG1 (NM_018440.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFG001864 | Human PAG1 cDNA Clone(NM_018440.3) | Inquiry |
| MiUTR1H-07465 | PAG1 miRNA 3'UTR clone | Inquiry |
| CDCB190642 | Rabbit PAG1 ORF clone (XM_002710654.2) | Inquiry |
| CDCR243350 | Mouse Pag1 ORF Clone(NM_001195031.1) | Inquiry |
| CDCR264498 | Mouse Pag1 ORF Clone(NM_053182.5) | Inquiry |
| CDCR303767 | Human PAG1 ORF Clone(NM_018440.3) | Inquiry |
Phosphoprotein associated with glycosphingolipid-enriched microdomains1 (PAG1) has shown with impact on immune receptor signaling in T and B cells as a transmembrane adaptor protein. Evidence from genome-wide association studies of asthma indicated that there is an association between the genetic variants responsible for the PAG1 expression regulation and asthma risk. However, whether the relatedness of PAG1 expression and asthma pathophysiology can be accounted by causality or not is still not fully understood. Lipid rafts resided transmembrane phosphotyrosylated adaptor protein is encoded by PAG1. Besides its dispensable role for T-cell development and function, negative regulation on T-cell immune responses of PAG1 has been reported. T-cell activation can be inhibited by PAG1 via protein tyrosine kinase CSK (C-terminal SRC kinase) upon T-cell receptor (TCR) stimulation. Loss of PAG1 can initiate T-cell hyper-activation and induction of a detrimental T-helper type1 (Th1) response in the experimental autoimmune encephalomyelitis. But the effect of PAG1 expression on the development of Th2 responses remains to be elusive. In contrast to SRC kinase Lyn inhibition followed by B-cell receptor signaling and B-cell activation, PAG1 works as a feedback-loop inhibitor in mast cells, where SRC kinase hyperphosphorylate PAG1. And increased recruitment of CSK to lipid rafts which in turn inactivates SRC kinases can be delivered to down-regulate mast cell activation and degranulation by the PAG1.
As the most common extracranial pediatric solid tumor, neuroblastoma has high mortality rates and association with tyrosine kinase c-Src, which is playing an important role in differentiation of NB cells. PAG1 (Cbp, Csk binding protein) was characterized as a central inhibitor of c-Src and other Src family kinases to function as a novel tumor suppressor in NB. Proliferation and anchorage-independent colony formation with increased activation of AKT and ERK downstream of c-Src can be promoted by PAG1 knockdown in NB cells, and these effects can be counteracted by PAG1 over-expression. In orthotopic xenograft model, NB tumorigenicity can be significantly inhibited by PAG1 over-expression. All those conditioned that reactivation of PAG1 and inhibition of c-Src kinase activity role as a novel therapeutic approach for high-risk NB.
Figure 1. PAG1 protein works as a transmembrane adaptor protein in the lipid raft signaling cluster for regulation of Src family kinase (SFKs), which is a convergent point for multiple pathways regulating N-methyl-D-aspartate (NMDA) receptors. (Fangkun Jing, et al. 2020)